Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital
Istanbul, Turkey (Türkiye)
NCT Number: NCT06385899
In Turkey, only 55% of patients with type 2 diabetes have been diagnosed, and 91% of these patients have been receiving treatment. The rate of patients reaching the treatment target is 50%. The pandemic has also affected diabetic patients. It is aimed to determine the characteristics of patients with type 2 diabetes (HbA1c >=10) with poor metabolic control and to evaluate the extent to which metabolic control can be achieved in 12 months.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Istanbul, Turkey (Türkiye)
Patients who applied to Istanbul Medeniyet University Goztepe Prof. Dr. Suleyman Yalcin City Hospital Diabetes Polyclinics and have an HbA1c levels of >= 10% in their examinations will be admitted to the study. Detailed history, including medication usage and previous blood tests will be questioned. The patients will be asked to complete questionnaires about their eating patterns (mindful eating questionnaire), their physical activities (General practice physical activity questionnaire), and whether the participants have depression (Beck depression questionnaire). Anthropometric measurements will be taken, and biochemical data will be recorded. Patients will be grouped according to their previous HbA1c values as a) newly diagnosed, b) those whose diabetes was previously controlled, c) those whose diabetes was previously not at the target range but now worsened, and d) those whose diabetes was poorly controlled from the beginning. Diabetes follow-up will be continued by their respective physicians. The patients will be called again three months after their enrollment to record the most recent biochemical data. Patient characteristics (age, gender, educational status, depression status, eating awareness, exercise characteristics) will be evaluated in accordance with the predetermined HbA1c groups. Again, according to the patient groups, the difference in HbA1c after three months, the frequency of reaching the target, and possible factors associated with the findings will be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: twelve months
Changes in HbA1c levels after 12 months treatment according to the predetermined HbA1c groups.
Time frame: twelve months
Comparison of the patient groups in their success in reaching the HbA1c target of equal to or below 7%
Time frame: twelve months
Educational status may have an impact on HbA1c reduction. Participants who have reached the HbA1c target are compared in terms of their educational level and those who have not.
Time frame: twelve months
The Beck Depression Index will be used to compare participants who reach the HbA1c target and those who do not
Time frame: twelve months
Physical activity is graded into 4 levels. Levels will be compared in participants who reach target HbA1c level and who do not
Time frame: twelve months
The effect of weight loss on reaching HbA1c target of 7% will be compared
Goztepe Prof Dr Suleyman Yalcın City Hospital
Other
The Effect of Close and Intensive Therapeutic Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01688778
Behavior, Diabetes Mellitus
Copenhagen, Copenhagen NV, Denmark
View Trial DetailsNCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial Details